Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $60.89.

HALO has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HALO. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares during the period. Janney Montgomery Scott LLC grew its position in Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after buying an additional 251,711 shares in the last quarter. Boston Trust Walden Corp increased its stake in Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 1.0 %

Shares of HALO stock opened at $54.80 on Monday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $54.09.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.